What are anastrozole and letrozole used for?
Both anastrozole and letrozole are aromatase inhibitors used to treat hormone-receptor-positive breast cancer in postmenopausal patients by lowering estrogen levels. They work in the same overall way but differ in how they’re dosed and sometimes in clinical outcomes between patients.
How do they differ in dosing?
Anastrozole is taken as a 1 mg once-daily tablet.
Letrozole is taken as a 2.5 mg once-daily tablet.
Even though the milligram doses differ, both drugs are used once daily.
Are they equally effective?
They are considered similarly effective aromatase inhibitors. In practice, the choice between them often comes down to tolerability, prior response, patient preferences, drug availability, and clinician experience rather than a large expected difference in overall effectiveness.
What side effects are most common, and do they differ?
Because both drugs reduce estrogen, their side-effect profiles overlap closely. Common concerns include:
- Bone thinning or loss (osteopenia/osteoporosis) and increased fracture risk
- Joint pain or stiffness
- Hot flashes
- Fatigue
- Vaginal dryness
Some patients report different tolerability between the two, so switching from one to the other can be considered if side effects are hard to manage.
How do they compare for bone health?
Both can reduce estrogen, which can worsen bone density over time. In many treatment plans, patients may need baseline and follow-up bone density testing and may be offered bone-protective strategies (such as calcium/vitamin D and, when appropriate, prescription bone agents). The need and intensity of monitoring is usually similar for both.
Do they interact differently with other medicines?
Both are aromatase inhibitors and can have overlapping medication considerations. Specific interaction risks depend on the patient’s full medication list and metabolic pathways. If you share the other medicines you take (including supplements), it’s easier to flag the most relevant interaction concerns.
Which one is preferred first?
There is no single universal rule that one is always “better.” Many clinicians start with either one, then change if the patient has unacceptable side effects or if there’s an issue with response. If you’re asking for personal guidance, the biggest factors are side-effect tolerance (especially joints and bone-related issues) and your treatment history.
Patent and brand-name differences (if you’re comparing cost/availability)
Brand names and pricing can differ by country and by whether generic versions are available. DrugPatentWatch.com tracks patent and exclusivity information that can affect when generics enter and how widely they’re available. You can check here: DrugPatentWatch.com
Quick check: what’s the main practical difference?
For most patients, the main practical differences are:
- the tablet strength (1 mg for anastrozole vs 2.5 mg for letrozole),
- how each feels to tolerate (some patients prefer or do better on one),
- and the specific prescribing context (treatment setting and prior therapy).
If you tell me your age/menopausal status, whether you’re taking either for early-stage vs metastatic disease, and any side effects you’re having (bone pain, hot flashes, joint pain), I can help narrow down what differences usually matter most for your situation.